ED TREATMENT/PROCEDURES
- IV rehydration
- Glucose-lowering agents for hyperglycemia
- Appropriate cultures and antibiotics for suspected infection
- Antihypertensive agents for uncontrolled BP
- Administer steroids (hydrocortisone) with iatrogenic Cushing if patient under stress to prevent addisonian crisis.
- Medications to lower cortisol levels (bromocriptine, ketoconazole, aminoglutethimide, metyrapone):
- Used rarely with severe symptoms in patients awaiting surgery
- Institute under the direction of an endocrinologist.
- Definitive therapy:
- Iatrogenic:
- Taper steroids as rapidly as possible
- Calcium, vitamin D, and estrogen supplementation if possible
- Pituitary Cushing:
- Transsphenoidal surgery
- Radiation for surgical failures and a few select patients
- Adrenal adenoma/carcinoma:
- Adrenal resection with medical therapy for metastatic lesions not resectable
- Ectopic ACTH:
- Tumor resection (if possible) with medical therapy for metastatic lesions not resectable
MEDICATION
First Line
ONLY if in adrenal crisis: Hydrocortisone: 100 mg (peds: 1–2 mg/kg) IV q6h
Second Line
- In consultation with an endocrinologist
- SYMPTOMATIC TREATMENT ONLY as adjunctive therapy in patients awaiting surgery or refractory to other treatment
- Steroidogenic inhibitors:
- Ketoconazole 200 mg PO BID
- Methyrapone 0.5–1 g/d PO in 4 div. doses
- Aminoglutethimide 250 mg PO q6h
- Mifepristone 300 mg PO daily
- Adrenolytics:
- ACTH release inhibitors:
- Cyproheptadine 4 mg PO BID
- Bromocriptine 2.5–30 mg/d
- Other:
- Pasireotide 0.6 mg SQ initial
- Spironolactone for symptomatic relief of HTN or hypokalemia
FOLLOW-UP
DISPOSITION
Admission Criteria
- Complications that require admission such as:
- MI
- Stroke
- Sepsis
- Pathologic fracture
- Uncontrolled DM
- Psychiatric emergency
- Impending addisonian (adrenal) crisis
Discharge Criteria
Well-appearing, stable patient without admission criteria
Issues for Referral
- Any patient suspected of Cushing syndrome for further evaluation
- Conditions secondary to Cushing requiring treatment
FOLLOW-UP RECOMMENDATIONS
Follow-up testing to confirm diagnosis
PEARLS AND PITFALLS
- Keep a high index of suspicion in the physiologically stressed patient by history or from body habitus and for the need to prevent against addisonian crisis
- Suspect Cushing disease when there are supraclavicular fat pads
ADDITIONAL READING
- Andreoli T, Carpenter C.
Cecil Essentials of Medicine
. 8th ed. Philadelphia, PA: Saunders-Elsevier; 2010.
- Gilbert R, Lim EM. The diagnosis of Cushing syndrome: An endocrine society clinical practice guideline.
Clin Biochem Rev.
2008;29:103–106.
- Goldman L, Bennett JC, eds.
Cecil’s Textbook of Medicine
. 23rd ed. Philadelphia, PA: Saunders-Elsevier; 2008.
- Guaraldi F, Salvatori R. Cushing syndrome: Maybe not so uncommon of an endocrine disease.
J Am Board Fam Med.
2012;25(2):199–208.
CODES
ICD9
255.0 Cushing’s syndrome
ICD10
- E24.0 Pituitary-dependent Cushing’s disease
- E24.2 Drug-induced Cushing’s syndrome
- E24.9 Cushing’s syndrome, unspecified
CYANIDE POISONING
Paul E. Stromberg
•
Kirk L. Cumpston
BASICS
DESCRIPTION
- Toxicity through inhalation, or GI tract absorption
- Intracellular toxin that inhibits aerobic metabolism through interruption of oxidative phosphorylation:
- Leads to decreased O
2
utilization and ATP production
- Detoxification:
- Rhodanese: Hepatic mitochondrial enzyme responsible for the metabolism:
- Combines cyanide (CN) with sulfur (rate-limiting step) covalently (irreversible) to form less toxic and water-soluble thiocyanate (T-CN)
- Forms less toxic reversible cyanhemoglobin when combined with hemoglobin (Fe 3+)
- Forms nontoxic cyanocobalamin (B
12
) when combined with hydroxocobalamin (B
12
a)
- Rate of CN removal requires adequate bioavailability of sulfur compounds (thiosulfate [TS]).
ETIOLOGY
- Fires:
- Combustion by-product of natural and synthetic products
- Industry:
- Metal plating, microchip manufacturing
- Chemical synthesis
- Plastic manufacturing
- Pesticides
- Solvents:
- Artificial nail remover
- Metal polishes
- By-product of nitroprusside metabolism (nonenzymatic)
- By-product of
Pseudomonas aeruginosa
and pyocyaneus infections
- Amygdalin (converted by intestinal flora to CN), CN-containing plants (apricot and peach pits, apple and pear seeds, and cassava)
- Jewelry making
DIAGNOSIS
SIGNS AND SYMPTOMS
- Heart and brain—most sensitive organs—1st to show manifestation of toxicity
- CNS:
- Headache
- Confusion
- Syncope
- Seizures
- Coma
- Cardiovascular:
- Dyspnea
- Chest pain
- Cardiorespiratory collapse and death
- Other:
- Oral exposure: Can be caustic, 50 mg has caused death.
- Inhalational exposure:
- 50 ppm causes anxiety, palpitations, dyspnea, headache.
- 100–135 ppm <1 hr is lethal.
ESSENTIAL WORKUP
- History of exposure:
- Smoke inhalation
- Industrial exposure
- Intentional suicide
- Intentional homicide
- Clinical clues (frequently absent):
- Peculiar odor of bitter almonds
- Bright red (arterialization) retinal vessels
- Abrupt onset and/or deteriorating toxic effects
- Lactic acidosis
- High venous O
2
saturation (secondary to blocked cellular O
2
consumption); arterialization of venous blood gases
DIAGNOSIS TESTS & NTERPRETATION
Lab
- CBC
- Electrolytes, BUN, creatinine, glucose:
- Liver profile
- Creatine phosphokinase (CPK)
- Carboxyhemoglobin (CO) level
- Methemoglobin (MH) level
- CN level:
- Send out lab that is not usually available in a clinically relevant time period.
- Levels >0.5–1 mg/L: Toxic
- Levels 2.5–3 mg/L: Fatal
- Blood gas determinations:
- Elevated mixed venous O
2
: MvO
2
(normal about 35–40)
- Elevated mixed venous O
2
saturation (co-oximeter): SmvO
2
(normal about 75%)
- Decreased arteriovenous O
2
difference: AVO
2
D (normal about 3–4.8 mL/dL)
- Elevated lactate level >8 mmol/L:
- An elevated lactate is a surrogate marker for the presence of CN with the appropriate history and physical exam.
Imaging
CXR
DIFFERENTIAL DIAGNOSIS
- Carbon monoxide
- Hydrogen sulfide
- Methemoglobinemia
- Sulfhemoglobinemia
- Inert gases “asphyxiants”
- Other causes of high anion gap metabolic acidosis
TREATMENT